These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 17242292)

  • 1. Cyclooxygenase inhibition and adverse remodeling during healing after myocardial infarction.
    Jugdutt BI
    Circulation; 2007 Jan; 115(3):288-91. PubMed ID: 17242292
    [No Abstract]   [Full Text] [Related]  

  • 2. COX-2 inhibitors--a lesson in unexpected problems.
    Drazen JM
    N Engl J Med; 2005 Mar; 352(11):1131-2. PubMed ID: 15713947
    [No Abstract]   [Full Text] [Related]  

  • 3. Coxibs and cardiovascular disease.
    Fitzgerald GA
    N Engl J Med; 2004 Oct; 351(17):1709-11. PubMed ID: 15470192
    [No Abstract]   [Full Text] [Related]  

  • 4. Celecoxib shown effective in preventing colon polyps.
    Nelson NJ
    J Natl Cancer Inst; 2006 May; 98(10):665-7. PubMed ID: 16705118
    [No Abstract]   [Full Text] [Related]  

  • 5. COX-2 selective non-steroidal anti-inflammatory drugs and cardiovascular disease.
    Ray WA; MacDonald TM; Solomon DH; Graham DJ; Avorn J
    Pharmacoepidemiol Drug Saf; 2003; 12(1):67-70. PubMed ID: 12616850
    [No Abstract]   [Full Text] [Related]  

  • 6. Cyclooxygenase-2 inhibition increases mortality, enhances left ventricular remodeling, and impairs systolic function after myocardial infarction in the pig.
    Timmers L; Sluijter JP; Verlaan CW; Steendijk P; Cramer MJ; Emons M; Strijder C; Gründeman PF; Sze SK; Hua L; Piek JJ; Borst C; Pasterkamp G; de Kleijn DP
    Circulation; 2007 Jan; 115(3):326-32. PubMed ID: 17210840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does the pro-hypertensive effect of cyclooxygenase-2 inhibitors account for the increased risk in cardiovascular disease?
    Messerli FH; Sichrovsky T
    Am J Cardiol; 2005 Sep; 96(6):872-3. PubMed ID: 16169380
    [No Abstract]   [Full Text] [Related]  

  • 8. [New anti-inflammatory analgetics--are they needed?].
    Paakkari I
    Duodecim; 1999; 115(20):2217-24. PubMed ID: 11973925
    [No Abstract]   [Full Text] [Related]  

  • 9. [Innovation of anti-inflammatory drugs--inhibition of cyclooxygenases].
    Guo ZR
    Yao Xue Xue Bao; 2005 Nov; 40(11):967-9. PubMed ID: 16499077
    [No Abstract]   [Full Text] [Related]  

  • 10. Cyclooxygenase-2 inhibitors and cardiovascular risk.
    Smith ER
    Can J Cardiol; 2005 Mar; 21(3):307-8. PubMed ID: 15776124
    [No Abstract]   [Full Text] [Related]  

  • 11. Trying times for painkiller choices. Vioxx, Bextra, and Celebrex can increase the risk for heart attack and other cardiovascular problems. So can the old standbys, like ibuprofen and acetaminophen.
    Harv Heart Lett; 2006 Oct; 17(2):1-3. PubMed ID: 17153752
    [No Abstract]   [Full Text] [Related]  

  • 12. [Cyclooxygenase inhibitors: a never ending story?].
    Macrì R; Manfredi C
    G Ital Cardiol (Rome); 2006 Jul; 7(7):505-7. PubMed ID: 16977790
    [No Abstract]   [Full Text] [Related]  

  • 13. The pain game.
    Wadman M
    Nature; 2007 Jul; 448(7152):400-1. PubMed ID: 17653159
    [No Abstract]   [Full Text] [Related]  

  • 14. Drug safety. FDA panel urges caution on many anti-inflammatory drugs.
    Couzin J
    Science; 2005 Feb; 307(5713):1183-5. PubMed ID: 15731414
    [No Abstract]   [Full Text] [Related]  

  • 15. COX-2 inhibitors--lessons in drug safety.
    Psaty BM; Furberg CD
    N Engl J Med; 2005 Mar; 352(11):1133-5. PubMed ID: 15713946
    [No Abstract]   [Full Text] [Related]  

  • 16. Painful lessons.
    Nat Struct Mol Biol; 2005 Mar; 12(3):205. PubMed ID: 15744317
    [No Abstract]   [Full Text] [Related]  

  • 17. [Clinical pharmacology of selective inhibitors of cyclooxygenase-2].
    Patrignani P
    Acta Otorhinolaryngol Ital; 2003 Aug; 23(4 Suppl 74):13-8, 37-40. PubMed ID: 15058604
    [No Abstract]   [Full Text] [Related]  

  • 18. Differences between COX-2-specific inhibitors: clinical and economic implications.
    Sonnenblick EH
    Am J Manag Care; 2002 Oct; 8(15 Suppl):S428-30. PubMed ID: 12416792
    [No Abstract]   [Full Text] [Related]  

  • 19. Non-steroidal anti-inflammatory drugs in orofacial pain management--an update.
    van der Bijl P; van der Bijl P
    SADJ; 2002 Aug; 57(8):328-31. PubMed ID: 12428528
    [No Abstract]   [Full Text] [Related]  

  • 20. Tolerability of cyclooxygenase 2 inhibitors and the advisability of oral challenge.
    Rodríguez M; Enrique E; Castello JV; de Mateo JA; Roca B; Malek T
    Ann Allergy Asthma Immunol; 2003 Dec; 91(6):589. PubMed ID: 14700447
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.